KKR backs monster $300M raise to build up a new-model biotech — designed by Neil Kumar and MIT’s Andrew Lo
Neil Kumar always wanted to build a different kind of biotech company at BridgeBio. And now the CEO has banked right under $300 million to continue construction work on the grand design as he thinks about growing the pipeline and starting their first marketing efforts.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.